FDA Loosens Otitis Media Antibiotic Requirements In Final Guidance
While it drops an invasive enrollment assay requirement, the revised guidance for drugs that fight childhood ear infections provides a clear path to getting pathogens targeted by an investigational anti-infective into labeling.
You may also be interested in...
FDA's draft guidance for developing drugs to treat acute bacterial otitis media offers sponsors four possible superiority study designs
Commercialization of the fixed-dose combo buys lifecycle management for Forest and should support future drug development for partner Adamas, the originator of the technology behind the combination.
President Obama’s proposed $56 billion Opportunity, Growth and Security Initiative would add nearly $1 billion to the NIH budget but it is funded by offsets that are likely nonstarters in Congress.